Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Springer International Publishing Switzerland 2015. The cure rate of patients with Hodgkin lymphoma has improved significantly over the past decades and today exceeds 80%, because of improved diagnostics, chemotherapy and radiotherapy. There is, however, a large variety of late effects following treatment for Hodgkin lymphoma including second malignancies, cardiovascular diseases, pulmonary toxicity, decreased fertility, hormonal disturbances, and soft tissue damage, leading to considerable excess morbidity and mortality. The overall, long-term burden of the toxicity of treatment is determined by a combination of all of these. The aim of this chapter is to describe the most important late cardiovascular and pulmonary toxicities following treatment for Hodgkin lymphoma, how to manage this toxicity in previously treated patients and how to minimise the risk as much as possible in future patients.

Original publication





Book title

Hodgkin Lymphoma: A Comprehensive Overview, Second Edition

Publication Date



411 - 425